The Effortless Sleep Method: Cure for Insomnia
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
How to Take a Sleep History
1/25/2015 How to take a sleep history Joan Santamaria Neurology Service and Multidisciplinary Sleep Disorders Unit Hospital Clínic of Barcelona 1.- Clinical history: Fundamental: the best “sleep test” Examination: helpful, but not always 2.- Investigations : Sleep tests: PSG, Video-PSG, respiratory polygraphy, MSLT, MWT, actimetry 3.- To rush into a sleep test without considering the history is of little use Taking a good sleep history The bed partner is essential By definition, people is unconscious during sleep Parasomnias, PLMs, Snoring, Sleep apnea, Seizures Daytime sleepiness may be neglected by some patients Even in insomnia patients, the bed partner information may be helpful 1 1/25/2015 Three main complaints I cannot sleep as much as I want (insomnia) Excessive daytime sleepiness (hypersomnia) Abnormal behaviors during sleep (parasomnias and other problems…noise, apnea, enuresis, seizures… ) What are the main questions? Nocturnal sleep characteristics Schedule of sleep during the week and week-end or holidays Latency to sleep, number of awakenings and cause (bathroom, pain, nightmare...) Time and type of final awakening (spontaneous/induced) Feel refreshed / tired on awakening? 23 1 4:30 6 8 Nocturnal sleep pattern Sleep onset insomnia 24 1:30 7:30 Delayed sleep phase 24 3 12 Week day Insufficient sleep 24 5:30 1 11 Week end (> 2 hrs additional sleep duration on week ends, high sleep efficiency) 2 1/25/2015 Sleep diary DEFINITION OF INSOMNIA Two key elements Nocturnal sleep: Difficulty in sleeping as much or as deep as one would -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease
brain sciences Perspective The Neuroprotective Effects of Melatonin: Possible Role in the Pathophysiology of Neuropsychiatric Disease Jung Goo Lee 1,2 , Young Sup Woo 3, Sung Woo Park 2,4, Dae-Hyun Seog 5, Mi Kyoung Seo 6 and Won-Myong Bahk 3,* 1 Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan 47392, Korea; [email protected] 2 Paik Institute for Clinical Research, Department of Health Science and Technology, Graduate School, Inje University, Busan 47392, Korea; [email protected] 3 Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea; [email protected] 4 Department of Convergence Biomedical Science, College of Medicine, Inje University, Busan 47392, Korea 5 Department of Biochemistry, College of Medicine, Inje University, Busan 47392, Korea; [email protected] 6 Paik Institute for Clinical Research, Inje University, Busan 47392, Korea; [email protected] * Correspondence: [email protected] Received: 16 September 2019; Accepted: 19 October 2019; Published: 21 October 2019 Abstract: Melatonin is a hormone that is secreted by the pineal gland. To date, melatonin is known to regulate the sleep cycle by controlling the circadian rhythm. However, recent advances in neuroscience and molecular biology have led to the discovery of new actions and effects of melatonin. In recent studies, melatonin was shown to have antioxidant activity and, possibly, to affect the development of Alzheimer’s disease (AD). In addition, melatonin has neuroprotective effects and affects neuroplasticity, thus indicating potential antidepressant properties. In the present review, the new functions of melatonin are summarized and a therapeutic target for the development of new drugs based on the mechanism of action of melatonin is proposed. -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
(12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO). -
Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway
Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder – Possible Role for Methoxyindole Pathway Hongjie Zhu1., Mikhail B. Bogdanov2., Stephen H. Boyle1, Wayne Matson3, Swati Sharma3, Samantha Matson3,4, Erik Churchill1, Oliver Fiehn5, John A. Rush6, Ranga R. Krishnan1,6, Eve Pickering7, Marielle Delnomdedieu8, Rima Kaddurah-Daouk1*, Pharmacometabolomics Research Network 1 Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina, United States of America, 2 Department of Neurology and Neuroscience Weill Cornell Medical College, New York, New York, United States of America, 3 Department of Systems Biochemistry, Bedford VA Medical Center, Bedford, Massachusetts, United States of America, 4 Massachusetts General Hospital, Boston, Massachusetts, United States of America, 5 Genome Center, University of California Davis, Davis, California, United States of America, 6 Duke-NUS Graduate Medical School, Singapore, Singapore, 7 Pfizer Global R&D, Clinical Research Statistics, Groton, Connecticut, United States of America, 8 Pfizer Global R&D, Neuroscience Clinical Research, Groton, Connecticut, United States of America Abstract Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). -
Partial Agreement in the Social and Public Health Field
COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this -
Sedative Hypnotics
Louisiana Medicaid Sedative Hypnotics The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request: • Prior authorization for non-preferred sedative hypnotics; OR • Clinical authorization for tasimelteon (Hetlioz®, Hetlioz LQ™). Additional Point-of-Sale edits may apply. Some of tThese agents may have Black Box Warnings and/or may be subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations. Please refer to individual prescribing information for details. ___________________________________________________________________________________ Non-Preferred Agents Approval Criteria for Initial and Reauthorization Requests • There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc.; AND • The requested medication has been prescribed for an approved diagnosis (if applicable); AND • Previous use of a preferred product - ONE of the following is required: o The recipient has had a treatment failure with at least one preferred product; OR o The recipient has had an intolerable side effect to at least one preferred product; OR o The recipient has documented contraindication(s) to all of the preferred products that are appropriate to use for the condition being treated; OR o There is no preferred product that is appropriate to use for the condition being treated; AND • By submitting the authorization request, the prescriber attests to the following: o The prescribing information for the requested medication has been thoroughly reviewed, including -
Parasomnias Revisited New Mexico Thoracic Society Sapna Bhatia Md 02/25/17 Objectives
PARASOMNIAS REVISITED NEW MEXICO THORACIC SOCIETY SAPNA BHATIA MD 02/25/17 OBJECTIVES • Appreciate the clinical semiology to help differentiate between REM and NREM parasomnias • Appreciate the ICSD III Classification Scheme for the major parasomnias • Understand management modalities including behavioral and pharmacological for NREM and REM parasomnias • Understand the difference between parasomnias and seizures WHAT ARE PARASOMNIAS? Undesirable motor, or verbal phenomena that arise from sleep or sleep-wake transition PARASOMNIAS: OVERLAPPING STATES REM PARASOMNIAS WAKE NREM PARASOMNIAS REM NREM PARASOMNIAS: DIFFERENTIAL DIAGNOSIS RBD Confusional Arousals Recurrent Isolated Sleep Paralysis Sleepwalking Nightmare Disorder Sleep Terrors WAKE Sleep Related Eating Disorder REM NREM PYSCHOGENIC SEIZURES SPELLS NFLE Dissociative Disorder ICSD II ICSD III REM Parasomnias • RBD • RBD • Recurrent Isolated Sleep • Recurrent Isolated Sleep Paralysis ICSD II VS ICSDParalysis III CLASSIFICATION• Nightmare Disorder • Nightmare Disorder Disorders of arousal • Confusional Arousals • Confusional Arousals (NREM sleep) • Sleepwalking • Sleep Walking • Sleep Terrors • Sleep Terrors • SRED Other Parasomnias • SRED • Sleep Related Dissociative • Sleep Related Dissociative Disorders Disorders • Sleep Enuresis • Sleep Enuresis • Catathrenia SDB • Catathrenia • Exploding Head Syndrome • Exploding Head syndrome • Sleep Related Hallucinations • Sleep Related Hallucinations • Parasomnia, Unspecified • Parasomnia, Unspecified • Parasomnia due to Drug or • Parasomnia -
Synthesis of Novel Quinazolino-Quinolones As Potential Antibacterial Agents
Available online a t www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 2011, 3 (4):440-448 (http://derpharmachemica.com/archive.html) ISSN 0975-413X CODEN (USA): PCHHAX Synthesis of novel quinazolino-quinolones as potential antibacterial agents C. Naveenkumar Reddy, * H. Rama Mohan * and D. Muralimohan Rao † *Aptuit Laurus Private Limited, ICICI Knowledge Park, Turkapally, Shameerpet, Hyderabad, India †Department of Chemistry, College of Engineering, JNT University, Kakinada, India ______________________________________________________________________________ ABSTRACT Synthesis of novel quinozolono-quinolones from 3-quinazolinones coupled with N-1 position of 6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate with a two carbon chain linker and to evaluate the biological activities. Key words: Quinazolono-quinolones, quinazolinone, quinolone, fluoro benzoic acids, anti bacterial activity. ______________________________________________________________________________ INTRODUCTION 1, 4-dihydro-4-oxo-6-fluoroquinoline-3-carboxylic acid derivatives are quinolone class of anti- bacterial agents [1], which are effective against a variety of gram-negative microorganisms . A number of fluoroquinolone subclass of antibacterial agents such as norfloxacin, ofloxacin, ciprofloxacin are in clinical use. Similarly quinazolinones and its derivatives, a class of quinazolone heterocyclic compounds are widely used as anti microbial agents. Among other pharmacological activities, quinazolinones are extensively used as hypnotic/sedatives -
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
life Review Drug Repurposing for the Management of Depression: Where Do We Stand Currently? Hosna Mohammad Sadeghi 1,†, Ida Adeli 1,† , Taraneh Mousavi 1,2, Marzieh Daniali 1,2, Shekoufeh Nikfar 3,4,5 and Mohammad Abdollahi 1,2,* 1 Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] (H.M.S.); [email protected] (I.A.); [email protected] (T.M.); [email protected] (M.D.) 2 Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran 3 Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] 4 Pharmaceutical Sciences Research Center (PSRC) and the Pharmaceutical Management and Economics Research Center (PMERC), Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran 5 Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran * Correspondence: [email protected] † Equally contributed as first authors. Citation: Mohammad Sadeghi, H.; Abstract: A slow rate of new drug discovery and higher costs of new drug development attracted Adeli, I.; Mousavi, T.; Daniali, M.; the attention of scientists and physicians for the repurposing and repositioning of old medications. Nikfar, S.; Abdollahi, M. Drug Experimental studies and off-label use of drugs have helped drive data for further studies of ap- Repurposing for the Management of proving these medications. -
New Drug Evaluation Monograph Template
© Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Abbreviated Class Update: Newer Drugs for Insomnia Month/Year of Review: November 2014 End date of literature search: August Week 3 2014 New drug(s): tasimelteon (Hetlioz™) Manufacturer: Vanda Pharmaceuticals Inc. suvorexant (Belsomra™) Merck & Co., Inc. Current Status of Preferred Drug List (PDL) Class: Preferred Agents: ZOLPIDEM TABLET Non Preferred Agents: ZALEPLON CAPSULE, ZOLPIDEM EXTENDED-RELEASE TABLET, ZOLPIMIST™, LUNESTA™, ROZEREM™, SILENOR™, EDULAR™, INTERMEZZO™ Prior Authorization (PA) Criteria: A quantity limit is in place to prevent chronic daily use of all sedatives (Appendix 2) and to determine if the diagnosis is funded. Treatment of sleep disorders without sleep apnea is not a funded diagnosis (Line 636) by Oregon Health Plan (OHP). Treatment of insomnia contributing to a covered comorbid condition is funded. Electronic step edits were incorporated into the PA process as recommended at the March 2014 P&T meeting to streamline this process. There is also a PA required to prevent a patient from receiving two concurrent oral sedative medications. Research Questions: Is there new comparative effectiveness or safety evidence since the last scan (literature search end date of Week 2, June 2013) of newer drugs for insomnia to warrant a change to the preferred drug list (PDL)? Is there evidence that tasimelteon or suvorexant is more effective or safer than currently available newer drugs for insomnia? Is there evidence that tasimelteon or suvorexant is more effective of safer for a sub-set of patients with insomnia? Conclusions: There is no new comparative evidence for newer drugs for insomnia since the last scan.